Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  3SBio Inc. (ADR)    

3SBIO INC. (ADR)
Mes dernières consult.
Most popular
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CNY)
Sales 2017 3 585 M
EBIT 2017 1 108 M
Net income 2017 899 M
Debt 2017 1 516 M
Yield 2017 0,42%
Sales 2018 4 529 M
EBIT 2018 1 458 M
Net income 2018 1 171 M
Debt 2018 928 M
Yield 2018 0,48%
P/E ratio 2017 24,24
P/E ratio 2018 18,61
EV / Sales2017 6,53x
EV / Sales2018 5,04x
Capitalization 21 882 M
More Financials
Company
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products.It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.The company... 
Sector
Pharmaceuticals
Calendar
08/28Earnings Release
More about the company
Surperformance© ratings of 3SBio Inc. (ADR)
Trading Rating : Investor Rating :
More Ratings
Latest news on 3SBIO INC. (ADR)
07/21 3SBIO : Notice of listing on the stock exchange of hong kong limited- strategic ..
07/21 3SBIO : Completion of issue of euro300,000,000 zero coupon convertible bonds due..
07/13 3SBIO : to issue EUR300m convertible bonds
07/13 3SBIO : Proposed issue of euro300,000,000 zero coupon convertible bonds due 2022
07/12 3SBIO : Proposed issue of euro denominated convertible bonds
06/09 3SBIO : Voluntary announcement - epiao received marketing authorization to launc..
06/09 3SBIO : Voluntary announcement - tpiao being granted an approval for drug clinic..
05/25 3SBIO : VOLUNTARY ANNOUNCEMENT - Right of Distribution and Promotion of New Prod..
05/25 3SBIO : Monthly Return of Equity Issuer on Movements in Securities for the month..
05/17 3SBIO : granted distribution right of insulin product in China
More news
Sector news : Biopharmaceuticals
08/23DJSHIRE PLC SHIRE PLC : Director/Pdmr Shareholding
08/23 JOHNSON & JOHNSON : Massive California verdict expands J&J's talc battlefield
08/23 JOHNSON & JOHNSON : Massive California verdict expands J&J's talc battlefield
08/23DJBAYER : Big Move Triggers 'Doubts' -- WSJ
08/22DJBAYER : Monsanto's $57 Billion Megadeal Faces Closer EU Scrutiny -- 2nd Update
More sector news : Biopharmaceuticals
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 10,5  CNY
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Jing Lou Chairman, President & Chief Executive Officer
Wei hong Xiao Chief Operating Officer
Bo Tan Chief Financial Officer & Executive Director
Zhenping Zhu Chief Scientific Officer, President-R&D
Dong Mei Su Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
3SBIO INC. (ADR)3 286
BIOGEN7.82%60 622
CSL LIMITED28.08%45 975
ALEXION PHARMACEUTICALS12.95%30 844
GRIFOLS SA24.10%17 125
BIOMARIN PHARMACEUTICAL-1.67%14 277